Corcept Therapeutics Inc (CORT)
59.07
+4.77
(+8.78%)
USD |
NASDAQ |
Nov 08, 13:03
Corcept Therapeutics Revenue (Annual): 482.38M for Dec. 31, 2023
Revenue (Annual) Chart
Historical Revenue (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 482.38M |
| December 31, 2022 | 401.86M |
| December 31, 2021 | 365.98M |
| December 31, 2020 | 353.87M |
| December 31, 2019 | 306.49M |
| December 31, 2018 | 251.25M |
| December 31, 2017 | 159.20M |
| December 31, 2016 | 81.32M |
| December 31, 2015 | 50.29M |
| Date | Value |
|---|---|
| December 31, 2014 | 26.55M |
| December 31, 2013 | 10.36M |
| December 31, 2012 | 3.307M |
| December 31, 2011 | |
| December 31, 2010 | |
| December 31, 2009 | 0.029M |
| December 31, 2008 | 0.209M |
| December 31, 2007 | 0.482M |
| December 31, 2006 | 0.294M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Annual) Range, Past 5 Years
306.49M
Minimum
2019
482.38M
Maximum
2023
382.11M
Average
365.98M
Median
2021
Revenue (Annual) Benchmarks
| ADMA Biologics Inc | 258.22M |
| Akebia Therapeutics Inc | 194.62M |
| Bioventus Inc | 512.34M |
| Alnylam Pharmaceuticals Inc | 1.828B |
| Catalyst Pharmaceuticals Inc | 398.20M |